Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adenovirus Type-5 vector vaccine (Globe Biotech)
- Development stage
- Preclinical
- Lead developer
- Globe Biotech
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Oral, Intramuscular, Intranasal
01
Overview
The Adenovirus Type-5 vector vaccine is a COVID-19 vaccine candidate developed by Globe Biotech Limited, a pharmaceutical company based in Bangladesh. This vaccine utilizes a replication-incompetent Adenovirus Type-5 (Ad5) platform as a viral vector to deliver genetic material encoding SARS-CoV-2 antigens into host cells. Once delivered, the antigens are expressed, stimulating both humoral (antibody-mediated) and cellular (T-cell) immune responses against the SARS-CoV-2 virus. It was one of three distinct vaccine platforms—alongside mRNA and DNA plasmid candidates—developed by Globe Biotech and was recognized in the World Health Organization's draft landscape of COVID-19 vaccine candidates at the pre-clinical stage in late 2020.
- Other names
- Globe Biotech Adenovirus Type-5 COVID-19 vaccineGlobe Biotech viral vector vaccine
02
Targets
LRP1 (Prolow-density lipoprotein receptor-related protein 1)SARS-CoV-2 spike
Beyond the preview
Go deeper on Adenovirus Type-5 vector vaccine (Globe Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adenovirus Type-5 vector vaccine (Globe Biotech).